Design of Novel Bioreductive Drugs

  • Paul Workman
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)


There is currently a great need and indeed considerable enthusiasm to search for new drug molecules with improved therapeutic selectivity in the major solid tumours. One approach is to screen novel structures for activity in biologically relevant models. This is the new approach taken by the United States National Cancer Institute which places much emphasis on panels of human cell lines to test natural products in vitro. An alternative strategy is to identify differences in biochemical structure and function between normal and neoplastic cells and to develop agents to exploit these novel targets on a rational basis. There are many new and exciting possibilities. The elaboration of agents which interfere with oncogene function, growth factors and their receptors, transmembrane signal transduction and so on, are good examples. Considerable attention is also being directed towards another exploitable target based on the aberrant physiology of solid tumours: cellular hypoxia [1].


Tumour Hypoxia Hypoxic Cell Cytochrome P450 Reductase Mouse Liver Microsome Flavone Acetic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Coleman CN: Hypoxia in tumors: A paradigm for the approach to biochemical and physiologic heterogeneity. JNCI 1988 (80):310–317PubMedGoogle Scholar
  2. 2.
    Thomlinson RH and Gray LH: The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955(9):539–549PubMedCrossRefGoogle Scholar
  3. 3.
    Hall EH: Radiobiology for the Radiologist. Harper and Row, New York 1988Google Scholar
  4. 4.
    Brown JM: Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism for reoxygenation. Br J Radiol 1979 (52):650–656PubMedCrossRefGoogle Scholar
  5. 5.
    Horseman MR and Overgaard J: Overcoming tumour radiation resistance resulting from acute hypoxia. Eur J Cancer 1992 (28A):717–718CrossRefGoogle Scholar
  6. 6.
    Rice GC, Hoy CA and Schimke RT: Transient hypoxia enhances the frequency of dihydrofolate gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci 1986 (83):5978–5982PubMedCrossRefGoogle Scholar
  7. 7.
    Wasserman TH, Sieman D and Workman P (eds): The Seventh International Conference on Chemical Modifiers of Cancer Treatment. Int J Radiat Oncol Biol Phys 1992 (22, Nos. 3 and 4):391–825Google Scholar
  8. 8.
    Brown JM and Workman P Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res 1980 (82):171–190PubMedCrossRefGoogle Scholar
  9. 9.
    Coleman CN, Wasserman TH, Urtasun RC, Halsey J, Hirst VK, Hancock S and Phillips TL: Phase I trial of the hypoxic cell radiosensitizer SR 2508: the results of the five to six week schedule. Int J Radiat Oncol Biol Phys 1986 (12):1105–1108PubMedCrossRefGoogle Scholar
  10. 10.
    Saunders MI, Anderson PJ, Bennett MH, Dische S, Minchington A, Stratford MRL and Tothill M: The clinical testing of Ro 03–8799 — pharmacokinetics, toxicology, tissue and tumor concentrations. Int J Radiat Oncol Biol Phys 1984 (10):1759–1763PubMedCrossRefGoogle Scholar
  11. 11.
    Roberts JT, Bleehen NM, Walton MI and Workman P: A clinical phase I toxicity study of Ro 03–8799: plasma, urine, tumour and normal brain pharmacokinetics. Br J Radiol 1986 (59):107–116PubMedCrossRefGoogle Scholar
  12. 12.
    Stratford IJ, O’Neill P, Sheldon PW, Silver ARJ, Walling JM and Adams GE: RSU 1069, a nitroimidazole containing an aziridine group. Biochem Pharmacol 1986 (35):105–109PubMedCrossRefGoogle Scholar
  13. 13.
    Horwich A, Holliday SB, Deacon JM, Peckham MJ: A toxicity and pharmacokinetic study in man of the hypoxic cell radiosensitizer RSU 1069. Br J Radiol 1986(59):1238–1243PubMedCrossRefGoogle Scholar
  14. 14.
    Jenkins TC, Naylor MA, O’Neill P, Threadgill MD, Cole S, Stratford U, Adams GE, Fielden EM, Suto MJ and Stier MA: Synthesis and evaluation 1 -[3-(2-haloethylamino)propyl)-2-nitroimidazoles as prodrugs of RSU 1069 and its analogs, which are radiosensitizers and bioreductively activated cytotoxins. J Med Chem 1990 (33):2603–2610PubMedCrossRefGoogle Scholar
  15. 15.
    Hall EJ, Astor MA, Biaglow J and Parham JC: The enhanced sensitivity of mammalian cells to killing by X-rays after prolonged exposure to several nitroimidazoles. Int J Radiat Oncol Biol Phys 1982 (8):447–451PubMedCrossRefGoogle Scholar
  16. 16.
    Stratford IJ, Adams GE, Horsman MR, Kandaiya S, Rajaratnam S, Smith E and Williamson C: The interaction of misonidazole with radiation, chemotherapeutic agents, or heat. Cancer Clin Trials 1980 (3):231–236PubMedGoogle Scholar
  17. 17.
    Workman P: Bioreductive mechanisms. Int J Rad Oncol Biol Phys 1992 (22):631–637CrossRefGoogle Scholar
  18. 18.
    Sartorelli AC: Therapeutic attack of solid tumours. Cancer Res 1988 (48):775–778PubMedGoogle Scholar
  19. 9.
    Oostveen EA and Speckamp WN: Mitomycin C analogues 1. Indoloquinones as potential bisalkylating agents. Tetrahedron 1987 (43):255–262CrossRefGoogle Scholar
  20. 20.
    Zeman EM, Brown JM, Lemmon MJ, Hirst VK and Lee WW: SR 4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1986 (12):1239–1242PubMedCrossRefGoogle Scholar
  21. 21.
    Brown JM and Koong A: Therapeutic advantage of hypoxic cells in tumors: a theoretical study. JNCI 1991 (83):178–185PubMedGoogle Scholar
  22. 22.
    Stratford IJ and Stephens MA: The differential hypoxic cell cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int J Radiat Oncol Biol Phys 1989 (16):973–976PubMedCrossRefGoogle Scholar
  23. 23.
    Binger M and Workman P: Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1 -aziridinomethyl)-2-nitro-1 H-imidazole-1 -ethanol (RSU 1069). Cancer Chemother Pharmacol 1991 (29):37–47PubMedCrossRefGoogle Scholar
  24. 24.
    Workman P, Binger M and Kooistra KL: Pharmacokinetics, distribution and metabolism of the novel bioreductive alkylating indoloquinone E09 in rodents. Int J Radiat Oncol Biol Phys 1992 (22):713–716PubMedCrossRefGoogle Scholar
  25. 26.
    Workman P and Walton MI: Enzyme-directed bioreductive drug development. In: Adams GE, Breccia A, Fielden EM, Wardman P (eds) Selective Activation of Drugs by Redox Processes. Plenum Press, New York 1991 pp 173–191Google Scholar
  26. 26.
    Walton MI and Workman P: Nitroimidazole bioreductive metabolism: quantitation and characterization of mouse tissue benznidazole nitroreductase in vivo and in vitro. Biochem Pharmacol 1987 (36):887–896PubMedCrossRefGoogle Scholar
  27. 27.
    Walton MI and Workman P: Enzymology of the reductive bioactivation of SR 4233: A novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem Pharmac 1990 (39):1735–1742CrossRefGoogle Scholar
  28. 28.
    Workman P, Walton MI, Wolf CR, Hemingway S and Riley RJ: Cytochrome P450s and cytochrome P450 reductase are the major enzymes in the reduction of the bioreductive SR 4233 (WIN 59075) by mouse liver microsomes. Proc Am Assoc Cancer Res 1992 (33):526Google Scholar
  29. 29.
    Siegel D, Gibson NW, Preusch PC and Ross D: Metabolism of mitomycin C by NAD(P)H: (quinone acceptor) oxidoreductase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 1990 (50):7483–7489PubMedGoogle Scholar
  30. 30.
    Walton MI, Suggett N and Workman P: The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys 1992 (22):643–647PubMedCrossRefGoogle Scholar
  31. 31.
    Riley R and Workman P: DT-diaphorase and cancer chemotherapy. Biochem Pharmac 1992 (43):1657–1669CrossRefGoogle Scholar
  32. 32.
    Knox RJ, Boland MP, Friedlos F, Coles B, Southan CS, Roberts JJ: The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC Biochem Pharmacol 1988 (37):4671–4677PubMedCrossRefGoogle Scholar
  33. 33.
    Walton MI, Smith PJ and Workman P: The role of NAD(P)H: quinone reductase (EC, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumour agent E09. Cancer Communications 1991 (3):199–206PubMedGoogle Scholar
  34. 34.
    Bailey SM, Suggett N, Walton MI and Workman P: Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones. Int J Radiol Oncol Biol Phys 1992 (64):649–653CrossRefGoogle Scholar
  35. 35.
    Walton MI, Wolf CR and Workman P: Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys 1989 (16): 983–986PubMedCrossRefGoogle Scholar
  36. 36.
    Workman P, Walton MI, Bibby MC and Double JA: In vitro response of mouse adenocarcinoma of the colon (MAC) tumours to indoloquinone E09: correlation with bioreductive enzyme content. Br J Cancer 1990 (62):215Google Scholar
  37. 39.
    Walton MI, Bibby MC, Double JA, Plumb JA and Workman P: DT-diaphorase activity correlates with sensitivity to the indoloquinone E09 in mouse and human colon carcinomas. Eur J Cancer 1992 (28A):1597PubMedCrossRefGoogle Scholar
  38. 38.
    Riley R and Workman P: Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H:(quinone-acceptor) oxidoreductase (EC purified from Walker 256 rat tumour cells. Biochem Pharmac 1992 (43):167–174CrossRefGoogle Scholar
  39. 39.
    Hoban PR, Walton MI, Robson CN, Godden J, Stratford U, Workman P, Harris AL and Hickson ID:Decreased NADPH: cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions. Cancer Res 1990 (50):4692–4697PubMedGoogle Scholar
  40. 40.
    Moulder JE and Rockwell S: Hypoxic fractions of solid tumours: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 1985 (11):323–329CrossRefGoogle Scholar
  41. 41.
    Vaupel P, Schlenger K, Knoop C and Hockell M: Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991 (51):3316–3322PubMedGoogle Scholar
  42. 42.
    Maxwell RJ, Workman P and Griffiths JR: Demonstration of tumour-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo. Int J Radiat Oncol Biol Phys 1989 (16):925–929PubMedCrossRefGoogle Scholar
  43. 43.
    Raleigh JA, Franko AJ, Treiber EO, Lunt JA and Allen PS: Covalent binding of a fluorinated 2-nitromidazole to EMT-6 tumours in BALB/c mice: detection by F-19 nuclear magnetic resonance spectroscopy at 2.35 T. Int J Radiat Oncol Biol Phys 1986 (12):1243–1245PubMedCrossRefGoogle Scholar
  44. 44.
    Jerabek PA, Patrick TB, Kilbourn MR, Dischino DD and Welch MJ: Synthesis and biodistribution of 18F-labelled fluoronitromidazoles: potential in vivo makers of hypoxic tissue. Appl Radiat lsot 1986 (37):599–605CrossRefGoogle Scholar
  45. 45.
    Urtasun RC, Chapman JD, Raleigh JA, Franko AJ and Koch CJ: Binding of 3H-misonidazole to solid human tumors as a measure of hypoxia. Int J Radiat Oncol Biol Phys 1986 (12):1263–1267PubMedCrossRefGoogle Scholar
  46. 46.
    Leliveld P, Double JA, Bibby MC, Stratford IJ and Moody CJ: Antitumour activity and bioreductive potential of the mitosene GBJ 584. Annal Oncol 1992(3, Suppl 1):101Google Scholar
  47. 47.
    Patterson LH, Maine JE, Cairns DC, Craven MR, Bennett N, Fisher GR, Ruparelia K and Giles Y: Use of N-oxides of DNA affinic anthraquinones as bioreductive prodrugs. Annal Oncol 1992 (3, Suppl 1):94Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • Paul Workman
    • 1
  1. 1.Cancer Research Campaign Beatson Laboratories, CRC Department of Medical OncologyUniversity of GlasgowBearsden, GlasgowUK

Personalised recommendations